Report : Patient Controlled Injectors Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product (Electronic Wearable Injectors, Mechanical Wearable Injectors, and Infusion Pumps); Application (Cancer Treatment, Auto-immune Treatment, Blood Disorders Treatment, and Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Mail Order Pharmacies), and Geography
Cancer Treatment Segment to Drive Growth of Global Patient Controlled Injectors Market, by Application
According to a new market research study of “Patient Controlled Injectors Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Product, Application, Distribution Channel, and Geography”, the global patient controlled injectors market is expected to reach US$ 2,969.47 million by 2027 from US$ 7,505.70 million in 2019. The market is estimated to grow at a CAGR of 12.4% from 2020 to 2027. The report highlights trends prevailing in the global patient controlled injectors market and the factors driving market along with those that act as hindrances.
The patient controlled injectors are the recent invention in the administration of injections. There are high-unmet needs of people/ HCPs or patient’s requiring the patient-controlled injectors, as it has greater ease and comfort than any other auto-injectors. These are ergonomically developed, and the design of patient-controlled injectors can help optimize self-care, making it easy for patients to handle the system and administer the dosages at just one press.
Based on application, the global patient controlled injectors market is segmented into cancer treatment, auto-immune treatment, blood disorders treatment, and others. In 2019, the cancer treatment segment held the largest share of the global patient controlled injectors market and anticipated to register the highest CAGR of 13.0% in the market during the forecast period. The segment is expected to witness substantial growth due to increasing adoption of injectors for cancer treatment. Moreover, the introduction of new injectable cancer drugs coupled with increasing prevalence of cancer are also projected to offer lucrative opportunity for the market growth.
The demand for patient controlled injectors increased during the pandemic. Factors such as increased patient population, shortage of healthcare resources, and ease of increased the adoption of injectors had positive impact on the market by certain extent. However, implementation of physical distancing policies and total shut down of businesses in order to prevent the viral infection disrupted the supply chain operations, which caused a negative impact on the market growth.
Gerresheimer AG; F. Hoffmann-La Roche Ltd.; Johnson and Johnson Services, Inc.; Ypsomed AG; Westbourne Medical Limited; Enable Injections; scPharmaceuticals Inc.; United Therapeutics Corporation; and BD are among the leading companies operating in the patient controlled injectors market.
The report segments Global Patient Controlled Injectors Market as follows:
By Distribution Channel